Dr. Rugo On Rationale For The Elaine Study In Esr1-Mutated Er+/Her2- Breast Cancer

Dr. Rugo on Rationale for the ELAINE Study in ESR1-Mutated ER+/HER2- Breast Cancer

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer

ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant

Lasofoxifene shows promise for women with ESR1-mutated mBC

ELAINE 1: LAS vs fulv in la ER+/HER2- mBC ESR1m + disease progression on AI and CDK4/6i inhibitors

Dr. Goncalves Describes Research Involving the ESR1 Mutation in Breast Cancer

Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 Study

OncBrothers: Practice-Changing Cancer Discussions

Dr. Rugo on Pathway Changes in Breast Cancer

Targeted Oncology

Dr. Graff Underscores Unmet Needs in ESR1-Mutated Breast Cancer

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast Cancer

Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer

Dr. Cristofanilli on Lasofoxifene in ESR1-Mutant Breast Cancer

Dr. Rugo on Unmet Needs Beyond Second-Line Treatment in HER2+ Breast Cancer

Breast Cancer: The Next Wave By Dr. Hope Rugo

Axiom Healthcare Strategies

Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer

Dr. Fuqua on ESR1 Mutations in Primary Breast Cancer

Targeted Oncology

Dr. Rugo on the Impact of Margetuximab Based on CD16A Fc Receptors in HER2+ Breast Cancer

Dr. Rugo Discusses Guidelines for Metastatic Breast Cancer Management

What does the future hold for SERDs in ER+ breast cancer?

Dr. Cristofanilli on Data With Lasofoxifene in ESR1-Mutant Breast Cancer